SBN seems to be one BIO stock flying well under the radar at the...

SBN seems to be one BIO stock flying well under the radar at the moment.

With only a $4 million market cap and around $1.5 million in the bank the upside from here could be huge.

SBN offer a Oraline product range that uses Lateral flow technology in their point of care device to test saliva for various substances eg. drugs.

This device can be used for personal and workplace purposes.

For example a workplace may choose to use their product to drug test all their workers on a regular basis on the spot or the police can use it for road side drug testing on the spot.

The oppertunities are endless and the market space it is in is worth Billions of dollars per annum and growing.

The need for such an accurate device has been well documented and if SBN can crack into this market then investors could be sitting on an absolte gem.

The company plans to have distribution and lincencing deals in place by Feb/March this year, so you can see serious revenues could only be 1-2 months away for just one of their products.

For such a small market cap company to have a product in such a big industry with massive upside is quite rare.

SBN offers great value to investors at current prices and wouldnt be surprised to see the market cap many multiples of where it is today once the commercial licencing annoucement comes out in the next 1-2 months which opens the door to some serious revenue and profits going forward.

Exciting times ahead for this little BIO it seems.

Good luck all....